Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr;35(2):257-265.
Frisoli M L, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-648.
Picardo M, Dell’Anna ML, Ezzedine K et al: Vitiligo. Nat Rev Dis Primers, 2015; 341(1): 15011 2. Xie H, Zhou F, Liu L et al: Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci, 2016; 81(1): 3 9
Richmond JM, Frisoli ML, Harris JE: Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol, 2013; 25(6): 676 82.
Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin. 2017; 35:245-255.
Jin Y, Andersen G, Yorgov D, et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet. 2016; 48:1418-1424.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview—part I: introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-491.
Bae JM, Lee SC, Kim TH, et al. Factors affecting quality of life in patients with vitiligo: a nationwide study. Br J Dermatol. 2018;178(1):238-244.
Krüger C., Schallreuter K.U. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012; 51(10):1206-1212].
Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol. 1985; 2:71-78.
Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2016; 74(2):295 302.
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003; 16:208-214.
Salzes C, Abadie S, Seneschal J, Whitton M, Meurant J-M ,et all. TheVitiligo Impact Patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Investig Dermatol.136(1):52 58/
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JPW. The burden of vitiligo: patient characteristics associated with quality of life. J Am Dermatol. 2009;61(3):411 20.
Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017; 35(2):117 28
Ezzedine K, Lim HW, Suzuki T. et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25(3):E1-13.
Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014; 28:755-762.
Alonso-Castro L, Rios-Buceta L, Vano-Galvan S, Moreno C, Soria-Rivas A, Jaen P. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma. J Am Acad Dermatol. 2013;69: e28-e29.
Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016; 43:787-791.
Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016; 152:45-51.
Sharma S, Sarkar R, Garg VK, Bansal S. Coexistence of lip-tip vitiligo and disseminated discoid lupus erythematosus with hypothyroidism: need for careful therapeutic approach. Indian Dermatol Online J. 2013; 4:112-114.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG , Harris JE . New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017 Jul;77(1):1-13.
Физическая и реабилитационная медицина. Национальное руководство.
Под редакцией Г.Н. Пономаренко. Москва, 2016г. Стр. 660.
Частная физиотерапия. Под редакцией Г.Н.Пономаренко Москва. 2005г. Стр.726.
Терапия больных псориазом, атопическим дерматитом и витилиго узкополосным средневолновым ультрафиолетовым излучением с длиной волны 311 нм. Медицинская технология № ФС-2006/250 от 15 августа 2006 года. Вестник дерматологии и венерологии. Вестник дерматологии и венерологии 2008; 3: 17-20.
Лечение больных псориазом методом ПУВА-ванн. Медицинская технология № ФС-2006/251 от 15 августа 2006 года. Вестник дерматологии и венерологии, 2008; 3: 21-24.
Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol. 2013; 168:756-761.
Taieb A, Alomar A, Bohm M et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168:5 19.
Kim YC, Kim YJ, Kang HY, Sohn S, Lee ES. Histopathologic features in vitiligo. Am J Dermatopathol. 2008; 30:112-116.
Kwinter J, Pelletier J, Khambalia A, Pope E. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007; 56:236-41.
Lotti T, Berti S, Moretti S. Vitiligo therapy. Expert Opin Pharmacother.22. 2009; 10:2779-85.
Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol. 1998; 134:1532-40.
Ezzedine K, Silverberg Na. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics. July 2016, 138 (1) e20154126.
Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2012;78(1):68-73.